Stuart L. Goldberg, MD

Stuart L. Goldberg, MD, discusses financial toxicities faced in hematology.

Stuart L. Goldberg, MD, hematologist, John Theurer Cancer Center, discusses the use of 4 FDA-approved agents for patients with acute myeloid leukemia (AML) with varying genetic alterations.

Stuart L. Goldberg, MD, chief medical officer, John Theurer Cancer Center, discusses precision medicine for patients with hematologic malignancies.